Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P62979
UPID:
RS27A_HUMAN
Alternative names:
Ubiquitin carboxyl extension protein 80
Alternative UPACC:
P62979; P02248; P02249; P02250; P14798; P62988; Q29120; Q6LBL4; Q6LDU5; Q8WYN8; Q91887; Q91888; Q9BQ77; Q9BWD6; Q9BX98; Q9UEF2; Q9UEG1; Q9UEK8; Q9UPK7
Background:
Ubiquitin-ribosomal protein eS31 fusion protein, also known as Ubiquitin carboxyl extension protein 80, plays a pivotal role in cellular processes. It functions in protein degradation, DNA repair, cell cycle regulation, and stress response through its involvement in polyubiquitin chain formation. Additionally, it is a component of the 40S subunit of the ribosome, contributing to ribosome biogenesis and RNA processing.
Therapeutic significance:
Understanding the role of Ubiquitin-ribosomal protein eS31 fusion protein could open doors to potential therapeutic strategies.